OncoZenge AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020
Operating Revenue	2.66	-	-	-	-	Upgrade
Other Revenue	0.12	0	0	-	-	Upgrade
Revenue	2.78	0	0	-	-	Upgrade
Revenue Growth (YoY)	278300.00%	-66.67%	-	-	-	Upgrade
Gross Profit	2.78	0	0	-	-	Upgrade
Selling, General & Admin	18.53	8.68	15.9	20.4	4.68	Upgrade
Research & Development	-	-	-	-	0.22	Upgrade
Other Operating Expenses	0.04	0	0	0	0	Upgrade
Operating Expenses	18.57	8.69	15.91	20.4	4.89	Upgrade
Operating Income	-15.79	-8.69	-15.9	-20.4	-4.89	Upgrade
Interest Expense	-0.17	-0	-	-	-	Upgrade
Interest & Investment Income	0.02	0	-	-	-	Upgrade
EBT Excluding Unusual Items	-15.94	-8.69	-15.9	-20.4	-4.89	Upgrade
Asset Writedown	-	-	-	-23.17	-	Upgrade
Pretax Income	-15.94	-8.69	-15.9	-43.57	-4.89	Upgrade
Income Tax Expense	-	-	-	3.08	-1.01	Upgrade
Net Income	-15.94	-8.69	-15.9	-46.65	-3.89	Upgrade
Net Income to Common	-15.94	-8.69	-15.9	-46.65	-3.89	Upgrade
Shares Outstanding (Basic)	12	12	12	12	12	Upgrade
Shares Outstanding (Diluted)	12	12	12	12	12	Upgrade
Shares Change (YoY)	3.56%	-	-	-0.53%	-	Upgrade
EPS (Basic)	-1.31	-0.74	-1.36	-3.98	-0.33	Upgrade
EPS (Diluted)	-1.31	-0.74	-1.36	-3.98	-0.33	Upgrade
Gross Margin	100.00%	100.00%	100.00%	-	-	Upgrade
Operating Margin	-567.06%	-868500.00%	-530066.67%	-	-	Upgrade
Profit Margin	-572.56%	-868800.00%	-530066.67%	-	-	Upgrade
EBITDA	-	-	7.27	2.77	-	Upgrade
EBITDA Margin	-	-	242200.00%	-	-	Upgrade
D&A For EBITDA	-	-	23.17	23.17	-	Upgrade
EBIT	-15.79	-8.69	-15.9	-20.4	-4.89	Upgrade
Revenue as Reported	2.78	0	0	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.